SEC. 5. PUBLIC-PRIVATE PARTNERSHIPS. 
(a) FINDINGS.—Congress makes the following find-
ings: 
(1) Partnerships between governments and the 
private sector (including foundations, universities, 
corporations, community-based organizations, and 
other nongovernmental organizations) are playing a 
critical role in the area of global health, particularly 
in the fight against neglected diseases, including 
HIV/AIDS, tuberculosis, and malaria. 
(2) These public-private partnerships improve 
the delivery of health services in developing countries 
and accelerate research and development of vaccines 
and other preventive medical technologies essential 
to combating infectious diseases that disproportion-
ately kill people in developing countries. 
(3) These public-private partnerships maximize 
the unique capabilities of each sector while com-
bining financial and other resources, scientific 
knowledge, and expertise toward common goals 
which cannot be achieved by either sector alone. 
(4) Public-private partnerships such as the 
International AIDS Vaccine Initiative, PATH’s Ma-
laria Vaccine Initiative, and the Global TB Drug 
Facility are playing cutting edge roles in the efforts 
to develop vaccines for these diseases. 
VerDate Aug 31 2005 
19:10 Mar 10, 2007
Jkt 059200
PO 00000
Frm 00009
Fmt 6652
Sfmt 6201
E:\BILLS\H1391.IH
H1391
ycherry on PROD1PC64 with BILLS
(5) Public-private partnerships serve as incen-
tives to the research and development of vaccines for 
neglected diseases by providing biotechnology compa-
nies, which often have no experience in developing 
countries, with technical assistance and on the 
ground support for clinical trials of the vaccine 
through the various stages of development. 
(6) Sustaining existing public-private partner-
ships and building new ones where needed are essen-
tial to the success of the efforts by the United States 
and others in the international community to find a 
cure for these and other neglected diseases. 
(b) SENSE OF CONGRESS.—It is the sense of Con-
gress that— 
(1) the sustainment and promotion of public- 
private partnerships must be a central element of 
the strategy pursued by the United States to create 
effective incentives for the development of vaccines 
and other preventive medical technologies for ne-
glected diseases debilitating the developing world; 
and 
(2) the United States Government should take 
steps to address the obstacles to the development of 
these technologies by increasing investment in re-
VerDate Aug 31 2005 
19:10 Mar 10, 2007
Jkt 059200
PO 00000
Frm 00010
Fmt 6652
Sfmt 6201
E:\BILLS\H1391.IH
H1391
ycherry on PROD1PC64 with BILLS
search and development and establishing market and 
other incentives. 
SEC. 6. COMPREHENSIVE STRATEGY FOR ACCELERATING 
THE DEVELOPMENT OF VACCINES FOR NE-
GLECTED DISEASES. 
(a) REQUIREMENT FOR STRATEGY.—The President 
shall establish a comprehensive strategy to accelerate ef-
forts to develop vaccines and microbicides for neglected 
diseases such as HIV/AIDS, malaria, and tuberculosis. 
Such strategy shall— 
(1) expand public-private partnerships and seek 
to leverage resources from other countries and the 
private sector; 
(2) include the negotiation of advance market 
commitments and other initiatives to create eco-
nomic incentives for the research, development, and 
manufacturing of vaccines and microbicides for HIV/ 
AIDS, tuberculosis, malaria, and other neglected 
diseases; 
(3) address intellectual property issues sur-
rounding 
the 
development 
of 
vaccines 
and 
microbicides for neglected diseases; 
(4) maximize United States capabilities to sup-
port clinical trials of vaccines and microbicides in 
developing countries; 
VerDate Aug 31 2005 
19:10 Mar 10, 2007
Jkt 059200
PO 00000
Frm 00011
Fmt 6652
Sfmt 6201
E:\BILLS\H1391.IH
H1391
ycherry on PROD1PC64 with BILLS
(5) address the issue of regulatory approval of 
such vaccines and microbicides, whether through the 
Commissioner of the Food and Drug Administration, 
or the World Health Organization, or another entity; 
and 
(6) expand the purchase and delivery of existing 
vaccines. 
(b) REPORT.—Not later than 180 days after the date 
of enactment of this Act, the President shall submit to 
the appropriate congressional committees a report setting 
forth the strategy described in subsection (a) and the steps 
to implement such strategy. 
SEC. 7. ADVANCE MARKET COMMITMENTS. 
(a) PURPOSE.—The purpose of this section is to im-
prove global health by creating a competitive market for 
future vaccines through advance market commitments. 
(b) AUTHORITY TO NEGOTIATE.— 
(1) IN GENERAL.—The Secretary of the Treas-
ury shall enter into negotiations with the appro-
priate officials of the World Bank, the International 
Development Association, and the GAVI Alliance, 
the member nations of such entities, and other inter-
ested parties for the purpose of establishing advance 
market commitments to purchase vaccines and 
microbicides to combat neglected diseases. 
VerDate Aug 31 2005 
19:10 Mar 10, 2007
Jkt 059200
PO 00000
Frm 00012
Fmt 6652
Sfmt 6201
E:\BILLS\H1391.IH
H1391
ycherry on PROD1PC64 with BILLS
(2) REPORT.—Not later than 180 days after 
the date of the enactment of this Act, the Secretary 
shall submit to the appropriate congressional com-
mittees a report on the status of the negotiations to 
create advance market commitments under this sec-
tion. This report may be submitted as part of the re-
port submitted under section 6(b). 
(c) REQUIREMENTS.—The Secretary of the Treasury 
shall work with the entities referred to in subsection (b) 
to ensure that there is an international framework for the 
establishment and implementation of advance market 
commitments and that such commitments include— 
(1) legally binding contracts for product pur-
chase that include a fair market price for a guaran-
teed number of treatments to ensure that the mar-
ket incentive is sufficient; 
(2) clearly defined and transparent rules of 
competition for qualified developers and suppliers of 
the product; 
(3) clearly defined requirements for eligible vac-
cines to ensure that they are safe and effective; 
(4) dispute settlement mechanisms; and 
(5) sufficient flexibility to enable the contracts 
to be adjusted in accord with new information re-
lated to projected market size and other factors 
VerDate Aug 31 2005 
19:10 Mar 10, 2007
Jkt 059200
PO 00000
Frm 00013
Fmt 6652
Sfmt 6201
E:\BILLS\H1391.IH
H1391
ycherry on PROD1PC64 with BILLS